SEC Comment Letter for RAPT Therapeutics, Inc. (RAPT) (CIK 0001673772) (RAPT) — Feb 3, 2020

RAPT Therapeutics, Inc. (RAPT) (CIK 0001673772)
Date: Feb. 3, 2020 · CIK: 0001673772 · Accession: 0000000000-20-001013

View on Edgar

AI Filing Summary & Sentiment

Date

February 3, 2020

Author

Not clearly detected

Form

UPLOAD

Company

RAPT Therapeutics, Inc. (RAPT) (CIK 0001673772)

Letter

February 3, 2020 Brian Wong, M.D., Ph.D. Chief Executive Officer RAPT Therapeutics, Inc. 561 Eccles Avenue South San Francisco, CA 94080 Re:RAPT Therapeutics, Inc. Draft Registration Statement on Form S-1 Filed January 28, 2020 CIK No. 0001673772 Dear Dr. Wong: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan James, Esq.

Show Raw Text

February 3, 2020
Brian Wong, M.D., Ph.D.
Chief Executive Officer
RAPT Therapeutics, Inc.
561 Eccles Avenue
South San Francisco, CA 94080
Re:RAPT Therapeutics, Inc.
Draft Registration Statement on Form S-1
Filed January 28, 2020
CIK No. 0001673772
Dear Dr. Wong:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Ryan James, Esq.

SecProbe.io